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Abstract 
Adverse reactions caused by drugs following their release into the market are among the leading causes of death in 
many countries. The rapid growth of electronically available health related information, and the ability to process 
large volumes of them automatically, using natural language processing (NLP) and machine learning algorithms, 
have opened new opportunities for pharmacovigilance. Survey found that more than 70% of US Internet users 
consult the Internet when they require medical information. In recent years, research in this area has addressed for 
Adverse Drug Reaction (ADR) pharmacovigilance using social media, mainly Twitter and medical forums and 
websites. This paper will show the information which can be collected from a variety of Internet data sources and 
search engines, mainly Google Trends and Google Correlate. While considering the case study of two popular 
Major depressive Disorder (MDD) drugs, Duloxetine and Venlafaxine, we will provide a comparative analysis for 
their reactions using publicly-available alternative data sources.  
 
Introduction 
Despite the continuous surge in developing drug therapies for major diseases, only 30% to 50% of patients has 
shown improvements, while approximately 7% of hospitalized patients experience adverse drug reactions
1
 (ADR). 
Adverse reactions caused by drugs following their release into the market are among the leading causes of death in 
many countries. Pharmacovigilance systems, also known as ‘‘early warning’’ systems have monitored ADRs since 
1960s by health agencies and societies including the World Health Organization
2
 (WHO). In the United States, The 
Food and Drug Administration (FDA) is the federal agency that is responsible for the protection and promotion of 
public health including the regulation and supervision of drugs
3
. Before its release to the market, a pharmaceutical 
product must go through rigorous testing, in clinical trials, for short-term safety and efficacy on a very limited 
number of subjected which were carefully chosen using restrictive inclusion an exclusion criteria
4
. However, the 
various limitations of clinical trials prevent a comprehensive assessment for the consequences of using a particular 
drug before its release
5
.  
 
In order to maximize the benefic effects, while reducing the risk of adverse reactions due to toxicity or sub 
therapeutic dosing, scholars and practitioners have expanded their pharmacovigilance efforts using different 
approaches. For instance, the rapid growth of electronically available health related information, and the ability to 
process large volumes of them automatically, using natural language processing (NLP) and machine learning 
algorithms, have opened new opportunities for pharmacovigilance that could address some of the above- mentioned 
limitations
6
. A recent survey found that more than 70% of US Internet users consult the Internet when they require 
medical information
7
. The data created by people who thus seek information offers an unprecedented opportunity 
for applications to monitor and improve the quality of life of people with a variety of medical conditions
8
. Although 
pharmacovigilance on Twitter data has been tackled by several studies
6, 9-13
, such data can be used in a variety of 
ways to the betterment of medical research and practice.  
 
Major depressive Disorder (MDD) is one of the most common mental disorders worldwide, affecting negatively the 
daily living for extended periods of time
14
. MDD is ubiquitous, resulting in almost 16 million disabilities in the 
United States
15
 and 350 million people worldwide
16 
each year. While major depressive disorder can develop at any 
age, it affects approximately 14.8 million American adults, or about 6.7 percent of the U.S. population age 18 and 
older, in a given year
17
. Moreover, studies have shown that MDD is more prevalent in women than in men
18
. In 
addition, people with depression are four times as likely to develop a heart attack as those without a history of the 
illness. After a heart attack, they are at a significantly increased risk of death or second heart attack
19
. Alongside the 
evolution and the increase in MDDs, scientists have worked avidly on developing antidepressant drugs. Historically, 
the treatment of MDD has mainly entailed several classes of medications, including tricyclic antidepressants, 
benzodiazepines, and selective serotonergic reuptake inhibitors
20 
(SSRIs). However, the widespread use of SSRIs 
vis-à-vis older antidepressant classes is predominantly because of their greater ease of use and more favorable side 
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effect profile
21
. More recently, serotonergic noradrenergic reuptake inhibitors (SNRIs), another group of evidence-
based pharmacological interventions for the MDD treatment, has been shown to be more efficacious than SRRIs
22-26
. 
Within SNRIs, previous studies have reported the superiority of duloxetine and venlafaxine for MDD treatment
27-28
. 
 
Both duloxetine and venlafaxine, sold under the brand names Cymbalta and Effexor respectively among others, are 
SNRIs designated for the treatment of MDD. Although they have similar mechanisms of actions, duloxetine has a 
more balanced affinity for both serotonin and norepinephrine transporters, whereas venlafaxine has a higher affinity 
for serotonin than norepinephrine transporters
29-30
. From one side, duloxetine inhibits the reuptake of serotonin and 
norepinephrine (NE) in the central nervous system. Duloxetine increases dopamine (DA) specifically in the 
prefrontal cortex, where there are few DA reuptake pumps, via the inhibition of NE reuptake pumps (NET), which is 
believed to mediate reuptake of DA and NE
31
.
 
However, duloxetine has no significant affinity for dopaminergic, 
cholinergic, histaminergic, opioid, glutamate, and GABA reuptake transporters and can therefore be considered to 
be a selective reuptake inhibitor at the 5-HT and NE transporters
32-33
. From the other side, venlafaxine blocks the 
transporter “reuptake” proteins for key neurotransmitters affecting mood, thereby leaving more active 
neurotransmitters in the synapse, such as: serotonin, norepinephrine, and dopamine
34
. 
In this paper, we presented our effort in analyzing and comparing the trends through the web content mining for 
duloxetine and venlafaxine. In addition to collecting and analyzing the data from Twitter, we also investigated the 
data from different sources, such as Google Trends and Google Correlate. We anticipate that our work could help 
highlight different data resources that can be applied in medical research for different drugs and classes 
 
Methods 
Google Trends: Google Trends is a public web facility of Google Inc. that provides a time series index of the 
volume of queries users enter into Google. The query index is based on query share: the total query volume for the 
search term in question within a particular geographic region divided by the total number of queries in that region 
during the time period being examined. The maximum query share in the time period specified is normalized to be 
100 and the query share at the initial date being examined is normalized to be zero
35
. The horizontal axis of the main 
graph represents time (starting from 2004), and the vertical is how often a term is searched for relative to the total 
number of searches. This query index data is available at country, state, and metro level for the United States and 
several other countries. On August 5, 2008, Google launched Google Insights for Search, a more sophisticated and 
advanced service displaying search trends data. On September 27, 2012, Google merged Google Insights for Search 
into Google Trends
36
. Google classifies search queries into about 30 categories at the top level and about 250 
categories at the second level using a natural language classification engine. After searching for a term, Google 
Trends provides a list of the most frequently searched with the term you entered in the same search session, within 
the chosen category, country, or region.  
To identify the reactions of patients on duloxetine and venlafaxine, we compared Trends of duloxetine (Cymbalta) 
and venlafaxine (Effexor) in the United States. Then, we analyzed the graph by inspecting the term’s popularity over 
time. We also examine different points on the graph where the letters represent news articles that might indicate why 
a certain term is spiking during that time period. Next, we found the related top searches for both drugs. 
Google Correlate: Google Correlate is an experimental new tool on Google Labs which enables you to find queries 
with a similar pattern to a target data series. The target can either be a real-world trend that you provide (e.g., a data 
set of event counts over time) or a query that you enter
37
. Google Correlate contains web search activity data from 
January 2003 to present and updated weekly. It computes the Pearson Correlation Coefficient (r) between your 
target query and the frequency time series for every query in Google database
38
. Correlation coefficients range from 
r=-1.0 to r=+1.0.  
To inspect the related interests of patients on duloxetine and venlafaxine, we searched for the correlated terms with 
duloxetine (Cymbalta) and venlafaxine (Effexor) in the United States. Then, we extracted and classified the related 
terms with the highest correlation coefficient (i.e. closest to r=1.0). 
Twitter Mining: To meet the objectives of this study, Twitter data was used to inspect the sharing and posting health 
related information for duloxetine and venlafaxine. The Diego Lab provides a manually annotated corpus for drugs 
related comments from mining the Twitter microblogging platform
39
. After filtering the target drugs from the 
corpus, we found 5640 duloxetine (Cymbalta) tweets and 6392 venlafaxine (Effexor) tweets between April 2013 and 
September 2015. First, we preprocessed the comment texts by lowercasing the characters and stemming all the terms 
using the Porter stemmer
40
. Then, we removed the stop words and extract the tokens using the Regexp tokenizer
41
. 
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Next, we identified the words that are most informative about the topic and genre of the tweets by calculating the 
frequency distribution of the tokens. Moreover, we extracted the main collocations from the tweets for both drugs 
using the Collocations finder
42
. Later, we conducted a sentimental analysis for the preprocessed tweets to inspect the 
satisfaction of patients with the studied drugs. For this analysis, we attempted to incorporate a score that represents 
the general sentiment of a comment (as the normalized sum of all the terms in the comment). Each word in a 
comment is assigned a score and the overall score assigned to the comment is equal to the sum of all the individual 
term sentiment scores, normalized by the length of the sentence in words. To obtain a score for each term, we used 
the Stanford sentimental analysis lexicon
42
. The overall score a sentence receives is therefore a floating point 
number with the range of -1 to 1.  
Results and Discussion 
Google Trends Analysis: After searching for Cymbalta and Effexor on Google Trends, the results showed the 
popularity variation for the inspected drugs. Figure 1 below shows that patients tend to be more interested into 
Cymbalta than Effexor. Furthermore, a consideration of the main events presented by letters reveals the reaction of 
patients with the drug milestones. For example, the approval of Cymbalta for muscle pain and chronic joint had a 
good impact on the web users for two years before dropping down again starting 2013.   
Figure 1. Google Trends for Cymbalta and Effexor. 
 
In addition, table 1 lists the top five related queries for each one of the investigated drugs. The related queries 
disclose the high interest of web users with the side effects of both drugs mainly. Moreover, users were interested 
into the withdrawal of drugs and their effects. Out of the top queries of Cymbalta is “pain” and that is what can be 
explained by the fact that FDA Approves Cymbalta was also approved in 2011 for Chronic Musculoskeletal Pain. 
Wellbutrin, a norepinephrine-dopamine reuptake inhibitor (NDRI) antidepressant drug, also appeared in the top 
queries related to Effexor.  
Table 1. Google Trends Top Related Queries. 
Cymbalta Top Related Queries Effexor Top Related Queries 
Side effects Cymbalta 100 Effexor XR 100 
Cymbalta generic 20 Side effects Effexor 95 
Cymbalta withdrawal 20 Effexor withdrawal 30 
Effects of Cymbalta 20 Wellbutrin 20 
Cymbalta pain 15 Effexor generic 20 
Approved for Muscle 
Pain and Chronic joint 
Cutting costs before 
Cymbal fades 
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The relationship between Effexor and Wellbutrin (also known as Bupropion) can be explained by the questions and 
posts of users on the web asking on the effects of taking both drugs together. For example, the following 
conversation is extracted from Drugs.com Questions and Answers: 
In 22 Oct 2014, Jlamar asked “Can I take Venlafaxine and Wellbutrin together? I have taken these drugs at different 
in the past?” The next day, Evrclr29 answered “Wellbutrin may make you more anxious so you might need to up 
your Effexor to make up for it”. 
Google Correlate Analysis: After searching for Duloxetine and Venlafaxine in Google Correlate, the top queries 
with a similar pattern to drugs data series were identified. Figures 2a and 2b illustrate the correlations geographically 
in the US with the top queries.  
Figure 2. Google Correlate Maps for (a) Duloxetine and (b) Venlafaxine.  
 
Table 2 and 3 below classify the top 20 queries for duloxetine and venlafaxine respectively into 
syndrome/disease/potential ADR, potential drug interactions, uses, and others. The results show that Google 
correlate can extract the top related queries and highlight some possible ADR that have not been announced or 
declared based on the users’ web searches. 
Tweets Analysis: An illustration of the main tokens is shown in figures 3(a) and 3(b) from the related tweets 
mentioning duloxetine and venlafaxine respectively. Figure 4 compares the results of sentimental analysis for both 
drugs. Although both drugs have close sentimental scores, Cymbalta users tend to be more satisfied with the drug as 
a result of specific events. The reasons behind these results alongside the events and milestones of both drugs will be 
investigated in future studies. Moreover, the top collocations are presented in table 4.  
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Table 2. Google Correlate Top Queries for Duloxetine 
 
Table 3. Google Correlate Top Queries for Venlafaxine 
Duloxetine Queries 
Correlation 
Factor 
Syndrome/Disease/ 
Potential ADR 
Potential Drug Interactions Uses Others 
pancreatitis 0.8967 X    
lantus 0.8947  X   
ziprasidone 0.8919  X   
generic names 0.8821    X 
ropinirole 0.8793  X   
tachycardia 0.8766 X    
benzodiazepines 0.8714  X   
bipap 0.8696 X    
quadrant pain 0.8696   X  
requip 0.8693  X   
chronic pancreatitis 0.8634 X    
dosing 0.8634    X 
upper quadrant pain 0.8621   X  
malformation 0.862 X    
lower quadrant pain 0.8615   X  
epididymitis 0.8606 X    
right upper quadrant pain 0.8598   X  
sinus tachycardia 0.8595 X    
pneumonia vaccine 0.8593  X   
incisional hernia 0.8566 X    
Venlafaxine Queries 
Correlation 
Factor 
Syndrome/Disease/ 
Potential ADR 
Potential Drug Interactions Uses Others 
bupropion 0.9181  X   
citalopram 0.9178  X   
sumatriptan 0.9081  X   
paroxetine 0.9028  X   
serotonin syndrome 0.8957 X    
granuloma annulare 0.8913 X    
steatohepatitis 0.8898 X    
annulare 0.8877 X    
sertraline 0.8793  X   
fluoxetine 0.8785  X   
amitriptyline 0.8759  X   
carbs in apple 0.871    X 
i love a rainy night 0.8706    X 
ostomy 0.8694 X    
diltiazem 0.8673  X   
ove a rainy night 0.8638l    X 
propranolol 0.8627  X   
lantus insulin 0.8626  X   
low back pain 0.8603   X  
mccarthy movies 0.8586    X 
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Figure 3. Word Cloud Presentations for (a) Duloxetine and (b) Venlafaxine.  
 
 
Figure 4. Sentimental Analysis Results for Effexor and Cymbalta 
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Table 4. Duloxetine and Venlafaxine Collocations 
 
Duloxetine  Venlafaxine  
Cymbalta help Take effexor 
Hurts cymbalta Side effects 
Depression hurts Effexor withdrawal 
Need cymbalta Taking effexor 
Take cymbalta Effexor effexor 
Cymbalta commercial venlafaxine withdrawal 
Help depression Feel like 
Help cymbalta Took effexor 
Help http Brain zaps 
Cymbalta depression Effexor made 
Side effects Effexor withdrawals 
Cymbalta can Dose effexor 
Cymbalta cymbalta Cold turkey 
Can help Last night 
Cymbalta helps Take venlafaxine 
Like cymbalta withdrawal symptoms 
Taking cymbalta Coming effexor 
Hurt cymbalta Get effexor 
Get cymbalta Effexor worst 
Cymbalta withdrawal Effexor like 
Feel like Like effexor 
Cymbalta doesn venlafaxine effexor 
Cymbalta right Effexor today 
Depression hurt Side effect 
Think cymbalta Think effexor 
Depression cymbalta Effexor makes 
Lyrica cymbalta Put effexor 
Doctor cymbalta Effexor works 
Cymbalta commercials Effexor really 
Cymbalta need Effexor dose 
  
Conclusion 
 
We have shown how web data can facilitate medical research, providing an overview of the state-of-the art in this 
area of Pharmacovigilance. While previous studies have relied mainly on Twitter and Medical forums and website to 
monitor the drugs and find ADR, we exposed the importance of information that we can extract from alternative 
data sources such as Google Trends and Google Correlate, while investigating the case study of duloxetine 
(Cymbalta) and venlafaxine (Effexor). This paper offers the researchers alternative tools to address medical 
questions using web data. We were, however, only able to analyze the trends and data from different sources 
separately. The main reason behind that is the large data imbalance associated with data collected from between 
Twitter and Google. In the future, we will also analyze the time series of events affecting the trends and correlation. 
Such analysis will aim to predict and forecast the trends of the drugs. We will also study the variation in drugs sales 
and prices and try to investigate the interaction between the satisfaction of patients and drug prices from one side 
and the sales from the other side.   
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